EligibleTrials

Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection

Recruiting · NCT05254782 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Health Network, Toronto

View the official record on ClinicalTrials.gov →
Lung cancer

What this trial is about

ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

3 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.